Clinical trial evaluates synthetic cannabinoid as brain cancer treatment

by Jackie Carr

(Medical Xpress)—Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

"In this Phase I study, we are examining the safety of multiple doses of dexanabinol, extent of penetration into the brain, and suitability for future trials," said Santosh Kesari, MD, PhD, principal investigator, and director of neuro-oncology, UC San Diego Moores Cancer Center. "What we hope to determine is the safe and optimal dose of drug in the brain."

Dexanabinol is a derivative that causes no psychotropic effects. It was tested previously as a neuroprotective in patients with . During these trials the drug was found to cross the blood-brain barrier.  More recently, researchers at e-Therapeutics plc, who are supporting the current trial, showed that dexanabinol kills cultured derived from many tumor types. Additional research in Kesari's lab demonstrated the drug's anti-cancer effects in patient-derived cell lines.

Dexanabinol's potential in fighting cancer was identified through a new approach to called network pharmacology, a way to analyze the network of proteins underlying a disease process. Network pharmacology enables scientists to seek drugs from among existing compounds, or design new molecules, that act simultaneously on a number of individual proteins to disrupt the cancer-related networks.

Kesari added that this trial fits well with a broader national effort to re-purpose existing drugs for the . He asked, "Why not use drugs that are currently available and learn how they can be applied in new effective ways for different indications?"

Dexanabinol is thought to act on proteins including NFĸB, TNFα, COX-2 HAT, FAT and cyclin-dependent kinases. The trial at UCSD Moores Cancer Center is one of two ongoing Phase I studies with dexanabinol, and the first to evaluate the drug in patients.

"In time, we will explore the association between the molecular phenotype of the tumor and the patient's response, which may allow us to personalize future therapies," said Kesari, associate professor, Department of Neurosciences at UC San Diego School of Medicine.

Patients who are eligible for this trial must have failed prior therapy including surgical resection, radiation therapy and systemic therapy.

add to favorites email to friend print save as pdf

Related Stories

Biomarker treatment for brain tumors studied

Jun 15, 2010

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain ...

Old drugs find new target for treating brain tumor

Nov 18, 2011

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel ...

Researchers discover non-surgical test for brain cancer

Apr 18, 2012

In a breakthrough for the way brain cancer is diagnosed and monitored, a team of researchers, lead by Anna M. Krichevsky, PhD, of the Center of Neurologic Diseases at Brigham and Women's Hospital (BWH) in Boston and Santosh ...

Recommended for you

Discovery could lead to new cancer treatment

Aug 29, 2014

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

Aug 29, 2014

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments